**TITLE PAGE**

# Age-Modulated Immuno-Metabolic Proteome Profiles of Deceased Donor Kidneys Predict 12-Month Posttransplant Outcome

**Authors:** Philip D Charles[1,2†], Sarah Fawaz[3,4*], Rebecca H Vaughan[3,4*], Simon Davis[2], Priyanka Joshi[3], Iolanda Vendrell[2], Ka Ho Tam[5], Roman Fischer[2], Benedikt M Kessler[2], Edward J Sharples[6], Alberto Santos[1,7,8], Rutger J Ploeg[3,4], Maria Kaisar[3,4†]

**Affiliations:**

[1]Big Data Institute, Nuffield Department of Medicine, University of Oxford; Oxford, United Kingdom.

[2]Target Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford; Oxford, United Kingdom.

[3]Research and Development, NHS Blood and Transplant; Bristol & Oxford, United Kingdom.

[4]Nuffield Department of Surgical Sciences and Oxford Biomedical Research Centre, University of Oxford; Oxford, United Kingdom.

[5]Engineering Department, University of Oxford; United Kingdom.

[6]University Hospital Oxford; Oxford, United Kingdom.

[7]Center for Health Data Science, University of Copenhagen; Copenhagen, Denmark.

[8]Novo Nordisk Foundation Center for Protein Research, University of Copenhagen; Copenhagen, Denmark.

*These authors contributed equally.

†Corresponding authors. Email: philip.charles@ndm.ox.ac.uk; maria.kaisar@nds.ox.ac.uk

**Keywords:**

Kidney transplantation, Machine Learning, Data Independent Acquisition, Proteomics, Donor age, QUOD

## ABSTRACT

Organ availability limits kidney transplantation, the best treatment for end-stage kidney disease. Deceased donor acceptance criteria have been relaxed to include older donors with higher risk of inferior posttransplant outcomes. More granular prediction models, based on deeper resolution organ assessment and understanding of damage processes, could substantially improve donor organ allocation and reduce graft dysfunction risk. Here, we profiled pre-implantation kidney biopsy proteomes from 185 deceased donors by high-resolution mass spectrometry and used machine learning to integrate and model these data, and donor and recipient clinical metadata to predict outcome. Our analysis and orthogonal validation on an independent cohort revealed 136

proteins predictive of outcome, 124 proteins of which showed donor-age modulated predictive effects. Observed associations with inflammatory, catabolic, lipid metabolism and apoptotic pathways may predispose donor kidneys to suboptimal posttransplant outcomes. Our work shows that integrating kidney proteome information with clinical metadata enhances the resolution of donor kidney quality stratification, and the highlighted biological mechanisms open new research directions in developing interventions during donor management or preservation to improve kidney transplantation outcome.

## TRANSLATIONAL STATEMENT

We profiled the proteome of pre-implantation biopsies selected from donor kidneys on the basis of paired 12-month graft function. Our data reveal a signature of proteins which contribute to transplant outcomes, many of these show different strengths of association dependent on donor age. The biological themes of the identified candidates reinforce immuno-metabolic and catabolic mechanisms as potential contributors to donor kidney susceptibility that may reduce graft recovery after transplantation.

## INTRODUCTION

Kidney transplantation is the optimal treatment for end-stage kidney disease. When compared to dialysis, transplantation profoundly increases life-expectancy, improves quality of life and is cost-effective. However, the lack of suitable donor organs for kidney transplantation limits the health benefits to patients with chronic kidney disease, and often prolongs dialysis treatment, with increased morbidity and mortality.

62 The shortage of organs, a decline in living donation in some countries and emerging
63 ageing populations have driven an increased utilization of older donor kidneys [1]. More than half
64 of all deceased donor kidneys now offered are from older donors [2].

65 Ageing is associated with a time-dependent decline of organ function, which is especially
66 evident in the kidney with the appearance of histologic lesions, such as tubular atrophy,
67 interstitial fibrosis, glomerulosclerosis, and arteriosclerosis. Kidney function progressively
68 declines with age, due to structural changes that cause a reduction of functioning glomeruli and
69 renal mass, podocyte dysfunction, and malfunction of mechanisms important in cellular repair [3].
70 Glomerular diseases are in turn more common and associated with worse outcomes in older
71 patients [4]. Age accelerates the transition from Acute Kidney Injury (AKI) to chronic injury [5] and
72 is an independent risk factor of graft dysfunction and graft loss for deceased donor kidneys [6],
73 furthermore, older donors are more likely to suffer from additional co-morbidity risk factors such
74 as diabetes, hypertension or cardiovascular disease.

75 Donor age has been incorporated in all clinical scoring algorithms to inform clinical
76 decision of donor kidney allocation [7,8]. However, donor age alone is insufficient to consistently
77 predict transplant outcomes. Current front-line models also include further clinical factors such
78 as terminal serum creatinine, history of hypertension and diabetes [8,9] and show consistent
79 performance across demographic cohorts but still only have a predictive accuracy of around 65%
80 [10]. Factors commonly included in these models may not reflect the nuances of biological
81 susceptibility to injury, subclinical trajectories of progression to dysfunction or capacity for renal
82 recovery.

83 The use of pre-implantation biopsies to supplement standard clinical scoring algorithms
84 has hitherto focused on histological scoring systems that assess evidence of chronic donor-

85 related damage, such as glomerulosclerosis or arteriolar changes [11]. Histology-based assessments
86 are particularly vulnerable to biopsy reproducibility issues, even under codified protocols.
87 Although small studies have suggested correlation with graft outcomes, there is only poor
88 correlation with kidney function in the recipient [12,13].

89 It is likely that molecular analyses could offer a clearer, higher resolution assessment of
90 organ state; but this requires deeper understanding of molecular phenotypes specifically
91 associated with poor outcomes rather than the immediate but potentially recoverable acute injury
92 sustained during the donor management process and organ retrieval. For example, deceased
93 donors are often assessed as having AKI based on serum creatinine levels [14], which implies an
94 inflammatory response, however AKI does not itself associate with longer term poor outcomes
95 [13–16], so we should not expect all inflammatory associated molecular signatures to be outcome-
96 associated. A broad picture analysis at relevant molecular phenotype levels is necessary; an
97 obvious first candidate is the proteome as this represents the end-state response associated with
98 both changes in expression and post-translational regulation.

99 Proteomic studies in donor kidneys have heretofore lacked the sample size to be
100 representative across donor age and demographic ranges [17], but advances in proteomic
101 technology such as data independent acquisition (DIA) mass spectrometry [18] now allow the
102 sensitivity and depth required for analysis of hundreds of samples to be practical. Larger
103 analyses are central towards taking the next steps toward precision medicine, and permit higher-
104 dimensional analysis (through the integration of proteomic profiles with clinical and
105 demographic phenotypes) to address the heterogenous demographic factors affecting patient
106 outcomes [19]. Machine learning approaches in particular offer powerful tools to extract the
107 maximum amount of knowledge from experimental cohorts given practical and cost limitations

108 of sample acquisition and analysis, and have been applied to disease staging, prediction of
109 disease recurrence, monitoring treatment response, and the identification of diagnostic,
110 prognostic, and predictive biomarkers [20,21].

111 Here, we benefit from the granularity provided by our MS-based proteomics profiling to
112 report age- and immunometabolism-related proteomic signatures in pre-implantation kidney
113 biopsies that are associated with suboptimal transplant outcomes against a clinical and
114 demographic variability background.

115

116 **METHODS**

117 **Study Design**

118 Deceased donor pre-transplantation kidney biopsies (n=186; 1 sample was later removed
119 during data QC) were obtained from the Quality in Organ Donor (QUOD) biobank, a national
120 multi-center UK wide bioresource of deceased donor clinical samples procured during donor
121 management and organ procurement.

122 Selection of biopsies of donor kidneys was based on paired 12-month post-transplant outcomes.
123 To minimize the impact of recipient factors on outcomes we only included kidneys for which the
124 contralateral kidney was transplanted and had similar 12-month post-transplant outcome. Donor
125 kidneys were selected to include the continuum of transplant outcomes i.e. the full range of
126 estimated Glomerular Filtration Rate (eGFR; specified throughout in units of ml/min/1.73 $m^2$)
127 from primary non-function to eGFR > 80) and, where possible, to exclude extreme demographic
128 or clinical factors. All clinical samples were linked to corresponding donor and recipient

129 demographic and clinical metadata, provided by NHS Blood and Transplant National Registry.
130 Detailed clinical and demographic data are summarized in Table 1.

131 **Study Approval and Ethics statement**

132 Informed consent from donor families was obtained prior to sample procurement.
133 Collection of QUOD samples and the research ethics approval was provided by QUOD
134 (NW/18/0187).

135 **Experimental Protocols and Statistical Analysis**

136 Please see Supplementary Methods.

137

138 **RESULTS**

139 **Donor clinical and demographic variable relevance for eGFR at 12-month posttransplant**

140 Kidney biopsies were obtained from Donation after Brain Death (DBD) donors and
141 Donation after Circulatory Death (DCD donors) at the back table immediately after kidney
142 procurement. To minimize the impact of factors related to post-procurement and recipient
143 characteristics, donors were selected on the basis of paired 12-month posttransplant outcomes.

144 For the purposes of exploratory analysis, we considered eGFR values in two ways.
145 Firstly, for comparison of clinical factors, we grouped 12 months posttransplant outcomes into
146 tertiles; Suboptimal Outcome (SO; eGFR $\leq 39$), Intermediate Outcome (IO; $40 < \text{eGFR} \leq 59$),
147 and Good Outcome (GO; eGFR $\geq 60$) (Figure 1). We refer to this henceforth as 'stratified
148 eGFR'. Secondly, all eGFR values (both recipient and donor) were rank-transformed so that,
149 where possible, we could test/model against a continuum of outcomes while mitigating against

150 factors introducing extreme values or values recorded as 0 due to graft failure. We refer to
151 'ranked eGFR' henceforth to indicate ranked recipient eGFR at 12 months posttransplant.

152 Clinical metadata confirmed that the selected donor groups were representative of the
153 donor population in the UK (UK Renal Registry, 2022[22]) (Table 1). Further, we found no
154 significant association between donor type and ranked eGFR (t-test; p = 0.2028). We then
155 investigated associations between clinical variables and stratified eGFR subgroups within DBD
156 and DCD, and between DBD and DCD within stratified eGFR subgroups (Supplementary Table
157 1). In DBD as in DCD, donor age was significantly different between the subgroups with SO
158 being older (Fisher's exact test; DBD: p = 4.285e-7; DCD: p = 2.080e-8). Among both DBD and
159 DCD donors there was a significant difference in UKKDRI between outcome groups (ANOVA
160 F-test; DBD: p = 1.515e-5; DCD: p = 7.006e-7). Histories of hypertension were different
161 between outcome subgroups (ANOVA F-test; DBD: p = 0.0010; DCD: p = 0.0336), but histories
162 of diabetes were not significantly different (ANOVA F-test; p = 0.1408; DCD: p = 0.2083).

163 Terminal serum creatinine levels were similar across outcome subgroups (ANOVA F-
164 test; DBD: p = 0.8601; DCD: p = 0.1755), although within the GO group it was higher in DBD
165 than in DCD (t-test; p = 0.0149).

166 After imputation of missing values, we examined the associations between clinical
167 variables common to both DBD and DCD donors, calculating a composite association score (see
168 methods) and then clustering by single linkage on association subtracted from 1 as a distance
169 measure (Figure 2). The strongest associations with ranked eGFR were donor age (Pearson's $r$ =
170 0.52), and recipient age ($r$ = 0.28). Donor history of hypertension and cardiological disease also
171 clustered closely using a single-linkage approach due to correlation with donor age ($r$ = 0.35 and

172 $r = 0.33$ respectively) but had a weaker direct correlation with outcome ($r = 0.30$ and $r = 0.23$
173 respectively).

174 **Unsupervised analysis of pretransplant kidney proteomes**

175 The proteomic analysis quantified 2984 protein groups with 50% or less missing values
176 (out of 7790 identified protein groups in total) over 185 samples and the 20 pool sample runs
177 (Supplementary Figure 1A). Analysis of the pool runs showed minimal technical variance over
178 the course of sample acquisition with a squared mean pairwise Z-corrected Pearson correlation
179 coefficient (a multi-way R-squared) of 0.94. Furthermore, six samples were paired biopsies from
180 the left and right kidneys of three donors. These samples showed high concordance in quantified
181 protein intensity values between pairs, with R-squared values of 0.71, 0.92 and 0.91 for each of
182 the three pair donors (Supplementary Figure 1B).

183 We performed an exploratory analysis of the proteomics data by Principal Component
184 Analysis (PCA) to look for underlying data trends. Most of the variance observed in the samples
185 was concentrated in the first two principal components (PC1: 20.01%; PC2: 13.38%; Figure 3A)
186 and K-means clustering identified 4 distinct clusters (Figure 3A).

187 Cluster membership associated with donor type, with a preponderance of DBD samples
188 towards Cluster 2 and a preponderance of DCD samples towards Cluster 4 (Figure 3B, upper left
189 panel; $p = 0.0235$). Sample clustering did not associate strongly with recipient eGFR at 12
190 months post transplantation ($p = 0.4134$), nor with donor eGFR ($p = 0.1684$), or donor age ($p =$
191 $0.7907$) (Figure 3B, upper middle and right and lower left panels). There was a weakly
192 significant association between cluster membership and donor BMI ($p = 0.0350$) and similarly
193 with serum creatinine ($p = 0.0326$) (Figure 3B, lower middle and right panels).

194 **Integration of kidney proteomes with clinical metadata enhances the resolution of donor**
195 **kidney quality stratification**

196 To identify possible clinical variable-protein interaction effect relationships with stratified
197 outcomes, we used a machine learning approach (Prediction Rule Ensembles [23]; PRE) to analyze
198 the set of all donor type-independent clinical variables and all quantified proteins, followed by
199 multivariate adaptive regression spline modelling[24] to assess individual protein relationships.

200 We first split our data into a training and test sets, excluding the six paired kidneys, and
201 sampling equally across stratified eGFR using a 2/3:1/3 train:test split. Feature selection and
202 predictive model training was performed on the training set only. The six paired kidneys were
203 reserved as a second 'biological duplicates' test set.

204 PRE modelling finds a minimal (but not necessarily the only minimal) set of predictors
205 for outcome in the form of decision tree, linear regression and multivariate adaptive regression
206 spline[25] rules. A single application of PRE does not yield an exhaustive list of predictive
207 candidates. We performed PRE in an iterative manner to 'mine' for candidate proteins, whereby
208 proteins, but not clinical variables, identified in the final ensemble of any previous model were
209 excluded from the dataset for future models. We performed 2000 iterations of PRE, generating
210 3282 rules across all ensembles. An immediate observation was that the primary contributor to
211 the rule cohort was donor age, featuring as a term in 3154 (~96.1%) rules; in comparison, protein
212 terms (collectively) featured in 198 (~6.0%) rules, while no other non-protein term yielded a
213 meaningful contribution – the next largest non-protein term was donor group, featuring in 5
214 (~0.1%) rules (Figure 4A). This process generated 195 selected proteins. As iterations passed
215 1000, the selection process became increasingly inefficient, in terms of iterations required to
216 identify another candidate protein. However new hits were still generated up to termination at

217 iteration 2000, suggesting there was more to find. Rather than continue with further iterations,
218 we supplemented the list of selected proteins with all other proteins that had high correlation
219 (Pearson's $r > 0.65$) with any of the 195 already selected proteins; this brought the list up to 255
220 selected protein features.

221 **Regression spline modelling reveals protein associations with posttransplant outcome are**
222 **modulated by donor age**

223 Next, we tested each of the 255 protein features for individual association with outcome,
224 beyond the effect of donor age alone. Since rank transformation is cohort specific, in order to
225 generate results which could be generalized to other cohorts we modelled against a specific
226 outcome binary, calibrated against a population-level threshold. Based on UK Renal Registry
227 Reports, UK median eGFR at 12 months posttransplant was approximately ~50.25 ml/min
228 (±0.24 standard error) across the weighted average for median DBD and DCD eGFR at 12
229 months posttransplant since 2013[22]; for simplicity we used a threshold of 50 (eGFR units
230 ml/min/1.73 $m^2$). We refer to 'sub-median outcome' henceforth to refer to recipient eGFR at 12
231 months posttransplant less than 50. Using multivariate adaptive regression spline modelling, we
232 generated predictive models for sub-median outcome using each protein, donor age, and any
233 potential age:protein interactions. This was performed in a regularized framework such that only
234 a minimal set of terms predictive of outcome were retained in each model. We then discarded
235 any protein that either did not feature in any term in its corresponding model, or whose model
236 gave a worse overall prediction error (Brier score[26]) than donor age alone.

237 After filtering we had identified 136 proteins which predicted sub-median outcome. We
238 performed a network analysis of shared Reactome pathways (Figure 4) and, using walktrap
239 clustering, found that these relationships were characterized by 4 major clusters; *Immune*

240 *Regulation and Complement Activation* (top 3 pathways 'Immune System', 'Innate Immune
241 System', 'Regulation Of Complement Cascade '), *Protein Metabolism and Regulation* (top 3
242 pathways: 'Metabolism Of Proteins', 'Post-translational Protein Modification' , 'Mitochondrial
243 Translation Elongation'), *Metabolism* (top 3 pathways: 'Metabolism', 'Metabolism Of Amino
244 Acids And Derivatives', 'Pyruvate Metabolism And Citric Acid (TCA) Cycle') and *Apoptosis*
245 (top 3 pathways: 'Developmental Biology', 'Role Of GTSE1 In G2/M Progression After G2
246 Checkpoint', 'Apoptosis').

247 For 124 proteins, the prediction included an age:protein interaction term where the
248 predictive effect of protein abundance was modulated by age, independent of the effect of age
249 alone or protein abundance alone (Figure 5). To visualize these effects, we used each model to
250 simulate the effect of increasing donor age with a high (90$^{th}$ percentile), median and low (10$^{th}$
251 percentile) abundance value for the protein (Figure 5A and Supplementary Figure 2). In all cases,
252 the chance of sub-median outcome was (unsurprisingly) driven primarily by donor age, with a
253 plateau at high donor age as a result of the low frequency of high-donor age, above-median
254 outcomes in both our data (<5% above age 60 in our training set) but also in the general
255 population. The difference in the modelled effect of changing protein abundance was striking;
256 the majority of proteins were positively associated with the chance of sub-median outcome
257 (simplistically, more protein = worse outcome), with the effect appearing to increase up to
258 around donor age 45-55. These included representative proteins for all four major clusters
259 including the known markers Cystatin-C (CST3; nephron function) and Vitronectin (VTN;
260 fibrosis) as well as a protein notorious for age-modulated associations with other diseases,
261 Apolipoprotein E (APOE). In contrast, several proteins were negatively associated with the
262 chance of sub-median outcome (simplistically more protein = better outcome), with the largest

263 effects shown by MAP2K1 and SLC27A2, with the latter in particular being modelled as having
264 minimal effect in donors younger than 40.

265 The full list of all 136 proteins, including a summary of age modulation effect, is given in
266 Supplementary Table 2. The selection and filtering steps are summarized in Figure 5B.

267 **Orthogonal validation confirms model performance, including age-modulated immuno-**
268 **metabolic impact on transplant outcomes**

269 We adopted two orthogonal approaches to validate our results. Firstly, we assessed the
270 performance of each model on test data. Going from train to test data, the models showed a small
271 increase in accuracy (Brier score; mean square error) and a small decrease in overall predictive
272 performance as measured by the area under the curve (AUC) (Figure 6A), indicating that the
273 models are generalizable. Most of the models (~110/136) showed high levels of accuracy with
274 negligible differences between test and train model performance.

275 Secondly, we selected several cluster-representative proteins (VTN, APOE, CST3 and
276 Prolactin Regulatory Element Binding; PREB) with well characterized available antibodies that
277 had good (AUC > 0.75) predicted outcome performance on our test data set (Figure 6B). We
278 investigated the predicted pattern of associations between protein abundance and outcome
279 (Figure 6C), by performing western blot validation of our results (Figure 6D). We selected
280 samples with remaining material from our cohort from the Good and Suboptimal Outcome
281 tertiles of our sample set, to compare protein abundance between younger (oldest sample 49) and
282 older (youngest sample 58) donors. Our western blot results were broadly consistent with the
283 associations anticipated by our modelling. For VTN, our model suggests a strong (and
284 strengthening with age) association between protein abundance and outcome in younger donors,
285 and we observed a significant difference in abundance between GO and SO outcome strata (t-

286 test; p=2.107e-9). In older donors, the model suggests a weaker (and weakening with age)
287 association, and we observed a mildly significant difference between abundance and outcome (t-
288 test; p=0.2450). For PREB, the model suggests a weaker association in younger donors than in
289 VTN since the age of maximum difference is shifted towards older donors. We did not observe
290 any significant difference by western (t-test; p=0.4530) in young donors. At older ages, the
291 model suggests a larger association in the older age range, weakening at an older age than VTN;
292 we observe a corresponding significant difference in PREB abundance by western blot (t-test,
293 p=8.800e-5). For APOE, the model suggests that the strongest association is over the middle of
294 the age range, where outcome changes rapidly with donor age. Younger donor samples did not
295 provide good coverage of the age range region of expected difference, and none was observed (t-
296 test, p=0.3719). In older donors, the effect of APOE difference weakens but remains present, and
297 consistent with that we saw a mildly significant difference in APOE abundance between
298 outcomes (t-test, p=0.0323). For CST3, the model again predicted a strong association in young
299 donors, which was consistent with the significant difference observed by western blot (t-test,
300 p=0.0084). In older donors the model actually predicts the association to weaken and even
301 reverse, such that GO samples would tend to have higher CST3 than SO samples; by western
302 blot, we saw a nonsignificant difference, but (in contrast to the prediction) still with a positive
303 median protein abundance difference from GO to SO. As a final check, we compared the
304 predicted outcome for each of the six paired kidneys from the second 'biological duplicates' test
305 set against their actual recipient eGFR at 12 months posttransplant (Figure 6E). All three kidney
306 pairs in this dataset had very consistent outcomes across pairs; two pairs with sub -median
307 outcome (15 and 36 ml/min; 23 and 27 ml/min) and one pair with much better outcome (72 and
308 81 ml/min). All four models assigned the four kidneys from two of the donors that went on to

309 have a sub-median outcome a probability of sub-median outcome greater than 0.5 (save in one
310 case for PREB, where the probability was ~0.48), and likewise assigned both kidneys from the
311 pair which both went on to have a good outcome a low probability of sub-median outcome.

312 **DISCUSSION**

313 Increasingly, kidneys from older donors are utilized for transplantation to expand the
314 deceased donor organ supply. The shortage of optimal organs, combined with increased
315 utilization of organs from older donors, increases risks of graft failure or functional decline. For
316 any individual donor organ, post-transplant outcomes remain hard to predict at the point of organ
317 acceptance. Here, we show that age-modulated kidney proteomic profiles improve risk
318 stratification of donor kidney quality, revealing clinically relevant age-protein interaction effects.

319 Donor age remains a key contributor in these clinical decisions and is rightfully one of
320 the most strongly weighted terms in extant scoring systems to determine kidney allocation [8,27]. In
321 our analysis, we found no obvious difference according to age when comparing donor kidney
322 proteomes by unbiased PCA. However, looking specifically at *outcomes*, it was the single most
323 important factor. PCA considers only a linear combination of variables and is ill-suited to
324 exploring nonlinear effects or interaction between variables. When we explored our data with our
325 iterative PRE feature selection approach, a substantial number of proteins were revealed to be
326 relevant.

327 The effect of donor age is not a novel finding, but it is particularly interesting to note that
328 pretransplant kidney proteomes were the second most powerful contributor to outcomes; and that
329 integration of the age and proteomic information resulted in enhanced prediction of 12 month
330 sub-median function. One factor often described as relevant to transplant outcome is donor type
331 [28]. This is certainly true at a clinical level in terms of donor management, and donation after

332 circulatory death is considered an adverse factor for transplant outcome in the US [7] (although not
333 in the UK [8,29]). Our initial PCA analysis found that non-supervised clustering of the sample
334 proteomes did partially separate samples by type. However, these differences did not extend to
335 association with outcome in our cohort. Not only did we fail to observe any direct association
336 between donor type and outcome, but donor type did not feature as an interaction term with any
337 protein identified by our iterative modelling. It is possible that such association may be obscured
338 by other sample characteristics associated with the overwhelming effect of donor age, especially
339 if the effect is relatively small. However, without disputing different donor type-specific
340 mechanisms for how kidney injury may be sustained [30], our data are consistent with previous
341 reports that the level of injury (rather than the cause) is the primary contributor towards the
342 potential for recovery [31].

343 Within our final list of 136 proteins associated with outcome there is a common theme of
344 implication in immune response to kidney injury (including both chronic injury, and acute
345 injury) particularly as a result of ischemic metabolic disruption. Our analysis of proteins
346 associated with outcome revealed that most (124/136 candidates) showed evidence of age-
347 moderated differences in their effect; in most cases, that as donor age increases, higher levels of
348 the protein become more negatively associated with outcome. The effect of second-order age
349 interactions, where the weightings of other terms are themselves age dependent, has not (to our
350 knowledge) been explored in terms of transplant outcome. Many of the proteins we find to be
351 age-moderated have known relevance, which is reassuring, however several have not previously
352 been reported in the context of transplant outcome or kidney dysfunction; it is possible the effect
353 of age modulation is key to fully understanding the links between molecular predictors and
354 transplant outcomes.

355 A prominent age-modulated example of a chronic injury associated marker in our
356 candidate list is VTN, a primary component of the extracellular matrix involved in in cell
357 adhesion, enhancing the activity of plasminogen activator inhibitor-1 (PAI-1), and inhibition of
358 the terminal complement pathway [32]. Vitronectin has been suggested as a biomarker of kidney
359 fibrosis although the mode of its multifaced action needs further investigation [33]. In addition,
360 examples for known acute injury associated markers include several complement components,
361 including two components of the membrane attack complex, C5 (in the form of C5b cleavage
362 product) and C8A, which has been associated with tissue injury resulting from
363 ischemia/reperfusion [34,35], Complement Component 1r (C1R), part of the activation complex for
364 the classical complement pathway[36], and Complement Factor B (CFB), a component of the
365 alternative pathway. Another candidate associated with immune regulation is Maltase
366 Glucoamylase (MGAM), characterized as an intestinal enterocyte but with expression in several
367 tissues including kidney, and whose presence in urinary exosomes been cited as a marker of AKI
368 in cirrhosis patients [37]. Finally, Mitogen-activated protein kinase 1 (MAP2K1, aka MEK1), as a
369 key component of the MAP kinase signal transduction pathway and therefore closely involved in
370 both cellular control and immune regulation (as part of TNFα signaling response[38]), is notable as
371 one of the few proteins for which higher abundance was associated with a reduced probability of
372 sub-median outcome, indicating resilience to injury. Increased TNFα is more usually associated
373 with renal injury[39], so this result is counterintuitive. The MAPK/ERK cascade impacts many
374 regulatory pathways so it is reasonable to assume such intuition may oversimplify the effect of
375 increased MEK1 abundance.

376 Several proteins in the age-moderated group are characterized as markers of protein
377 regulation and proteasomal activity. These may indicate alterations within the proteostasis

378 network that increase susceptibility of donor grafts to subsequent injury and reduce capacity for
379 recovery. CST3 is particularly noteworthy as, measured in serum, it is a known and effective
380 general biomarker for kidney function and has previously been reported as having predictive
381 power for outcomes in transplant recipients [40–42]. Our evidence indicates a further association
382 between CST3 levels in the donor kidney tissue and outcome; moreover, that this effect is age
383 dependent, starting around age 40. Interestingly, serum CST3 is relatively independent of age in
384 children and young adults [43], but numerous studies have demonstrated an increase in later years,
385 as summarized by Edinga-Melenge *et al.* [44]. These two age related effects may be
386 interconnected.

387 We found the age-modulated candidate PREB (Prolactin Regulatory Element Binding
388 protein) biologically interesting for three reasons. Firstly, there is a well characterized
389 relationships between kidney dysfunction (in the form of CKD), cardiovascular disease and
390 prolactinemia[45], with CKD patients being associated with elevated prolactinemia. Secondly, it is
391 a regulator of glucose homeostasis in the liver and therefore a plausible key node for metabolic
392 regulation in kidneys as well[46], acknowledging the large emphasis in our pathway analysis on
393 metabolic functions. Thirdly, it has a predicted[47] role in exit from the endoplasmic reticulum and
394 the unfolded protein response, which has an association with CKD via NFκB -mediated
395 inflammation[48].

396 Another age-moderated protein, APOE stands out as having previously reported age-
397 related associations with disease and organ dysfunction, in both cases including Alzheimer's
398 Disease (AD). APOE plays an important role in lipid metabolism to regulate the growth and
399 survival of mesangial cells and preserve kidney function [49]; not only is APOE protein a marker
400 for outcome in transplant recipients [50–52], there is also evidence for particular *APOE* genetic

401 alleles being associated with dysfunction risk [53–55], possibly manifested directly by lipidomic
402 differences between allelic profiles [56]. *APOE* alleles are further implicated in a host of disorders
403 including age-moderated association with AD risk [57] (with the strongest effect manifesting
404 around age 65 [58]), macular dysfunction, atherosclerosis and pulmonary scarring [59,60]. There is
405 also evidence of allele risk association between disparate pathologies [61]. Interestingly, we have
406 previously observed small (not statistically significant) increases in APOE due to ischemic
407 reperfusion injuries [62] which may be explained by a recently description of the role of APOE in
408 mediating senescence[63]. Such evidence suggests cause for further investigation of the *APOE*
409 genotype with respect to donor kidneys of varying age. Indeed, the lipoprotein genetic
410 background in general, with the close links between lipidome status and kidney function, may be
411 associated with outcome. There is evidence of at least one similar allele dependent effects in
412 another apolipoprotein (APOL1) associated with transplant outcome [64].

413 Organ allocation algorithms impose a close link between donor and recipient age in the
414 sample cohort, so these two variables cannot be conclusively separated. It is difficult to assess
415 whether the age-moderated effects we observe represent a tendency for greater damage in older
416 donors, or alternatively a greater ability to repair a given level of damage in younger recipients.
417 Our analysis considers only chronological donor age, rather than a more nuanced representation
418 of the epigenomic biological clock [65], which is likely to account for some variation observed
419 with respect to both donors and recipients.

420 Our list of outcome-associated candidates, controlling for the effect of donor age,
421 including those for which we further report an additional age-moderated effect, is almost
422 certainly not exhaustive. Practicalities of sample acquisition limited sampling of a range of
423 outcomes for donors outside the 30-60 age range. In our dataset, as in the general population,

424 there is a trend towards lower eGFR (fewer good outcome events) at high donor age (Table 1). In
425 the vast majority of proteins, the modelling suggests a plateauing effect at high donor age where
426 the differences in outcome due to both protein and age are smaller. This effect may be an artifact
427 of the distribution of sub-median outcomes. It is also immediately clear from our results that the
428 strength of the donor age factor is enormous relative to any one protein effect; this must be borne
429 in mind when interpreting model fits; at high donor age, the age effect is liable to dominate any
430 prediction weighting and reduce the accuracy of estimated protein contribution. Both of these
431 considerations should ideally be explored in a much larger cohort. High-throughput proteomics
432 techniques continue to advance rapidly and larger cohort sizes are ever more feasible [66] but
433 fundamental limitations on organ acquisition remain. Archiving at scale of clinical samples in
434 bioresources such as the Quality in Organ Donation (QUOD) biobank to parallel advancements
435 in big data analysis and interpretation platforms will improve the granularity in evidence-based
436 decision making and accelerate the translation and application to clinical practice.

437 In our orthogonal validation of selected proteins, the expected protein abundance
438 difference between extremes of the eGFR continuum across donor age distribution tails, and the
439 plateauing/narrowing of outcome differences at high donor age were broadly consistent with the
440 western blot results. In younger donors the predicted strengths of association were very
441 consistent with the observed differences in protein abundance in selected samples by western
442 blot. In older donors, the western blot results were still broadly consistent (relative to the effect at
443 in younger donors) in terms of a much weaker association, but the differences in both VTN and
444 PREB were larger than might be expected by examination of the prediction curves (Figure 6B,
445 upper panel) and the prediction for CST3 of a small reversal of the effect is both unexpected and
446 biologically counterintuitive. A better explanation is that the model fit is impacted by the

447 (unavoidable) lack of outcome diversity at high age ranges, with the CST3 'flip' in terms of
448 protein effect likely being artefactual.

449 In this work, we profiled the proteome of pre-implantation biopsies selected from donor
450 kidneys on the basis of paired 12-month graft function, limiting potential surgical and post-
451 transplant biases on transplant outcomes. Using machine learning and multivariate adaptive
452 spline regression models, we identified 136 candidate proteins associated with sub-median
453 outcomes, suggesting molecular signatures which may refine models of graft dysfunction based
454 on clinical and demographic factors alone. We also found that most (124) of these candidates
455 furthermore show different strengths of association dependent on the age of the donor. The
456 biological themes of the identified candidates reinforce known immuno-metabolic mechanisms
457 of kidney injury but raise interesting possibilities for further work, especially with regard to
458 donor genetic background. Furthermore, our results strongly suggest that for any studies of
459 subclinical molecular indicators with regard to kidney transplant outcomes, the possibility of
460 donor age-moderated weighting should be considered as a matter of course.

461

462 **SUPPLEMENTARY MATERIALS**

463 Supplementary Methods
464 Supplementary Table 1: Clinical variable p-values for association with donor type and outcome
465 Supplementary Table 2: Summary of results for all candidate proteins
466 Supplementary Figure 1: Protein Quantification Missingness
467 A: Missingness comparison: Proteins are shown ranked by the number of missing values
468 across all samples and the twenty standard pools, excluding one run which was removed
469 due to low signal. 2984 proteins had missing values in 50% or less runs.

470 B: Paired Kidney Comparison: Protein abundance values from paired kidneys (left/right)
471 from 3 individual donors were compared, as these are effectively biological replicates. x
472 axes: value in left kidney. y axes: value in right kidney. Inset: R-squared value
473 Supplementary Figure 2: Prediction of sub-median outcome differences between high and low
474 protein across donor age, for all shortlisted proteins with a predicted age modulation effect
475 Black traces: prediction at median protein abundance. Purple trace: prediction at 90th
476 percentile of protein abundance. Orange traces: prediction at 10th percentile of protein
477 abundance. The corresponding point on the main figure thus indicates the age at which
478 the difference between orange and purple lines is greatest.

479

480 **DATA AND MATERIALS AVAILABILITY**

481 The mass spectrometry proteomics data have been deposited to the ProteomeXchange
482 Consortium via the PRIDE [67] partner repository with the dataset identifier PXD033428.

483

484 **DISCLOSURE AND FUNDING**

485 This study was funded by NHS Blood and Transplant WP15-07 awarded to MK & RJP. SF was
486 supported by Kidney Research UK, grant reference KS_RP_002_20210111 awarded to MK.
487 PDC was supported by a Chinese Academy of Medical Sciences 2018-I2M-2-002 awarded to
488 BMK. Authors declare that they have no competing interests.

489 **Author contributions:**

490 Conceptualization: MK

491 Methodology: PDC, SF, RV, SD, RF, BMK, AS, ES, RJP, MK

492 Investigation: PDC, SF, RV, PJ, SD, IV, KT, AS

493 Visualization: PDC

494 Funding acquisition: BMK, RJP, MK

495 Project administration: MK

496 Supervision: RF, AS, MK

497 Writing – original draft: PDC, ES, MK

498 Writing – review & editing: All authors

499

500 **REFERENCES**


501 1. Callaghan CJ, Mumford L, Pankhurst L, Baker RJ, Bradley JA, Watson CJE. Early
502 Outcomes of the New UK Deceased Donor Kidney Fast-Track Offering Scheme.
503 *Transplantation*. 2017;101(12):2888-2897. doi:10.1097/TP.0000000000001860

504 2. Summers DM, Johnson RJ, Hudson AJ, et al. Standardized deceased donor kidney donation
505 rates in the UK reveal marked regional variation and highlight the potential for increasing
506 kidney donation: a prospective cohort study†. *Br J Anaesth*. 2014;113(1):83-90.
507 doi:10.1093/bja/aet473

508 3. Denic A, Glassock RJ, Rule AD. The Kidney in Normal Aging: A Comparison with Chronic
509 Kidney Disease. *Clin J Am Soc Nephrol*. 2022;17(1):137-139. doi:10.2215/CJN.10580821

510 4. O'Hare AM, Choi AI, Bertenthal D, et al. Age affects outcomes in chronic kidney disease. *J*
511 *Am Soc Nephrol*. 2007;18(10):2758-2765. doi:10.1681/ASN.2007040422

512 5. Ishani A, Xue JL, Himmelfarb J, et al. Acute Kidney Injury Increases Risk of ESRD among
513 Elderly. *J Am Soc Nephrol*. 2009;20(1):223-228. doi:10.1681/ASN.2007080837

514 6. Summers DM, Johnson RJ, Hudson A, Collett D, Watson CJ, Bradley JA. Effect of donor
515 age and cold storage time on outcome in recipients of kidneys donated after circulatory death
516 in the UK: a cohort study. *Lancet*. 2013;381(9868):727-734. doi:10.1016/S0140-
517 6736(12)61685-7

518 7. Rao PS, Schaubel DE, Guidinger MK, et al. A comprehensive risk quantification score for
519 deceased donor kidneys: the kidney donor risk index. *Transplantation*. 2009;88(2):231-236.
520 doi:10.1097/TP.0b013e3181ac620b

521 8. Watson CJE, Johnson RJ, Birch R, Collett D, Bradley JA. A Simplified Donor Risk Index
522 for Predicting Outcome After Deceased Donor Kidney Transplantation. *Transplantation*.
523 2012;93(3):314-318. doi:10.1097/TP.0b013e31823f14d4

9. Neuberger J, Callaghan C. Organ utilization - the next hurdle in transplantation? *Transpl Int*. 2020;33(12):1597-1609. doi:10.1111/tri.13744

10. Clayton PA, Dansie K, Sypek MP, et al. External validation of the US and UK kidney donor risk indices for deceased donor kidney transplant survival in the Australian and New Zealand population. *Nephrol Dial Transplant*. 2019;34(12):2127-2131. doi:10.1093/NDT/GFZ090

11. Remuzzi G, Cravedi P, Perna A, et al. Long-Term Outcome of Renal Transplantation from Older Donors. *N Engl J Med*. 2006;354(4):343-352. doi:10.1056/NEJMoa052891

12. Husain SA, Chiles MC, Lee S, et al. Characteristics and Performance of Unilateral Kidney Transplants from Deceased Donors. *Clin J Am Soc Nephrol*. 2018;13(1):118-127. doi:10.2215/CJN.06550617

13. Liu C, Hall IE, Mansour S, Thiessen Philbrook HR, Jia Y, Parikh CR. Association of Deceased Donor Acute Kidney Injury With Recipient Graft Survival. *JAMA Network Open*. 2020;3(1):e1918634. doi:10.1001/jamanetworkopen.2019.18634

14. Yu K, Husain SA, King K, Stevens JS, Parikh CR, Mohan S. Kidney nonprocurement in deceased donors with acute kidney injury. *Clin Transplant*. Published online August 4, 2022:e14788. doi:10.1111/ctr.14788

15. Hall IE, Akalin E, Bromberg JS, et al. Deceased-donor acute kidney injury is not associated with kidney allograft failure. *Kidney Int*. 2019;95(1):199-209. doi:10.1016/j.kint.2018.08.047

16. Mansour SG, Khoury N, Kodali R, et al. Clinically adjudicated deceased donor acute kidney injury and graft outcomes. *PLoS One*. 2022;17(3):e0264329. doi:10.1371/journal.pone.0264329

17. von Moos S, Akalin E, Mas V, Mueller TF. Assessment of Organ Quality in Kidney Transplantation by Molecular Analysis and Why It May Not Have Been Achieved, Yet. *Front Immunol*. 2020;11:833. doi:10.3389/fimmu.2020.00833

18. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. *Mol Cell Proteomics*. 2012;11(6):O111.016717. doi:10.1074/mcp.O111.016717

19. Raynaud M, Aubert O, Divard G, et al. Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. *The Lancet Digital Health*. 2021;3(12):e795-e805. doi:10.1016/S2589-7500(21)00209-0

20. Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. *Mol Syst Biol*. 2017;13(9):942. doi:10.15252/msb.20156297

21. Connor KL, O'Sullivan ED, Marson LP, Wigmore SJ, Harrison EM. The Future Role of Machine Learning in Clinical Transplantation. *Transplantation*. 2021;105(4):723-735. doi:10.1097/TP.0000000000003424

561 22. UK Renal Registry. *UK Renal Registry 24th Annual Report - Data to 31/12/2020*.; 2022.
562 https://renal.org/audit-research/annual-report

563 23. Fokkema M. Fitting prediction rule ensembles with R package pre. *J Stat Softw*.
564 2020;92(1):1-30. doi:10.18637/jss.v092.i12

565 24. Friedman JH. Multivariate Adaptive Regression Splines. *aos*. 1991;19(1):1-67.
566 doi:10.1214/aos/1176347963

567 25. Milborrow. Derived from mda:mars by T. Hastie and R. Tibshirani. S. *Earth: Multivariate*
568 *Adaptive Regression Splines*.; 2011. http://CRAN.R-project.org/package=earth

569 26. Brier GW. Verification Of Forecasts Expressed In Terms Of Probability. *Mon Weather Rev*.
570 1950;78(1):1-3. doi:10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2

571 27. Li B, Cairns JA, Robb ML, et al. Predicting patient survival after deceased donor kidney
572 transplantation using flexible parametric modelling. *BMC Nephrol*. 2016;17(1):51.
573 doi:10.1186/s12882-016-0264-0

574 28. Gill J, Rose C, Lesage J, Joffres Y, Gill J, O'Connor K. Use and Outcomes of Kidneys from
575 Donation after Circulatory Death Donors in the United States. *J Am Soc Nephrol*.
576 2017;28(12):3647-3657. doi:10.1681/asn.2017030238

577 29. Robinson C. *NHSBT Policy POL186/10. Kidney Transplantation: Deceased Donor*
578 *Allocation*.; 2019. https://nhsbtdbe.blob.core.windows.net/umbraco-assets-
579 corp/16915/kidney-allocation-policy-pol186.pdf

580 30. Vaughan RH, Kresse JC, Farmer LK, et al. Cytoskeletal protein degradation in brain death
581 donor kidneys associates with adverse post-transplant outcomes. *Am J Transplant*. Published
582 online December 8, 2021. doi:10.1111/ajt.16912

583 31. Kosmoliaptsis V, Salji M, Bardsley V, et al. Baseline donor chronic renal injury confers the
584 same transplant survival disadvantage for DCD and DBD kidneys. *Am J Transplant*.
585 2015;15(3):754-763. doi:10.1111/ajt.13009

586 32. De Lorenzi V, Sarra Ferraris GM, Madsen JB, Lupia M, Andreasen PA, Sidenius N.
587 Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in
588 vitronectin. *EMBO Rep*. 2016;17(7):982-998. doi:10.15252/embr.201541681

589 33. Carreras-Planella L, Cucchiari D, Cañas L, et al. Urinary vitronectin identifies patients with
590 high levels of fibrosis in kidney grafts. *J Nephrol*. 2021;34(3):861-874. doi:10.1007/s40620-
591 020-00886-y

592 34. Diepenhorst GMP, van Gulik TM, Hack CE. Complement-mediated ischemia-reperfusion
593 injury: lessons learned from animal and clinical studies. *Ann Surg*. 2009;249(6):889-899.
594 doi:10.1097/SLA.0b013e3181a38f45

595 35. Arias-Cabrales CE, Riera M, Pérez-Sáez MJ, et al. Activation of final complement
596 components after kidney transplantation as a marker of delayed graft function severity. *Clin*
597 *Kidney J*. 2021;14(4):1190-1196. doi:10.1093/ckj/sfaa147

598 36. Almitairi JOM, Venkatraman Girija U, Furze CM, et al. Structure of the C1r-C1s interaction
599 of the C1 complex of complement activation. *Proc Natl Acad Sci U S A*. 2018;115(4):768-
600 773. doi:10.1073/pnas.1718709115

601 37. Awdishu L, Tsunoda S, Pearlman M, et al. Identification of Maltase Glucoamylase as a
602 Biomarker of Acute Kidney Injury in Patients with Cirrhosis. *Crit Care Res Pract*.
603 2019;2019:5912804. doi:10.1155/2019/5912804

604 38. Sabio G, Davis RJ. TNF and MAP kinase signalling pathways. *Semin Immunol*.
605 2014;26(3):237-245. doi:10.1016/j.smim.2014.02.009

606 39. Ernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory kidney
607 diseases. *Kidney Int*. 2009;76(3):262-276. doi:10.1038/ki.2009.142

608 40. Coll E, Botey A, Alvarez L, et al. Serum cystatin C as a new marker for noninvasive
609 estimation of glomerular filtration rate and as a marker for early renal impairment. *Am J*
610 *Kidney Dis*. 2000;36(1):29-34. doi:10.1053/ajkd.2000.8237

611 41. Christensson A, Ekberg J, Grubb A, Ekberg H, Lindström V, Lilja H. Serum cystatin C is a
612 more sensitive and more accurate marker of glomerular filtration rate than enzymatic
613 measurements of creatinine in renal transplantation. *Nephron Physiol*. 2003;94(2):19-27.
614 doi:10.1159/000071287

615 42. Rodrigo E, Ruiz JC, Fernández-Fresnedo G, et al. Cystatin C and albuminuria as predictors
616 of long-term allograft outcomes in kidney transplant recipients. *Clin Transplant*.
617 2013;27(2):E177-83. doi:10.1111/ctr.12082

618 43. Bökenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J. Cystatin C--a
619 new marker of glomerular filtration rate in children independent of age and height.
620 *Pediatrics*. 1998;101(5):875-881. doi:10.1542/peds.101.5.875

621 44. Edinga-Melenge BE, Yakam AT, Nansseu JR, et al. Reference intervals for serum cystatin C
622 and serum creatinine in an adult sub-Saharan African population. *BMC Clin Pathol*.
623 2019;19:4. doi:10.1186/s12907-019-0086-7

624 45. Dourado M, Cavalcanti F, Vilar L, Cantilino A. Relationship between Prolactin, Chronic
625 Kidney Disease, and Cardiovascular Risk. *Int J Endocrinol*. 2020;2020:9524839.
626 doi:10.1155/2020/9524839

627 46. Park JM, Kim MY, Kim TH, Min DK, Yang GE, Ahn YH. Prolactin regulatory element-
628 binding (PREB) protein regulates hepatic glucose homeostasis. *Biochim Biophys Acta Mol*
629 *Basis Dis*. 2018;1864(6 Pt A):2097-2107. doi:10.1016/j.bbadis.2018.03.024

630 47. Gaudet P, Livstone MS, Lewis SE, Thomas PD. Phylogenetic-based propagation of
631 functional annotations within the Gene Ontology consortium. *Brief Bioinform*.
632 2011;12(5):449-462. doi:10.1093/bib/bbr042

633 48. Mohammed-Ali Z, Cruz GL, Dickhout JG. Crosstalk between the unfolded protein response
634 and NF-κB-mediated inflammation in the progression of chronic kidney disease. *J Immunol*
635 *Res*. 2015;2015:428508. doi:10.1155/2015/428508

636 49. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A Protective Role for Kidney
637 Apolipoprotein E: REGULATION OF MESANGIAL CELL PROLIFERATION AND
638 MATRIX EXPANSION. *J Biol Chem*. 2001;276(52):49142-49147.
639 doi:10.1074/JBC.M104879200

640 50. Kahraman S, Kiykim AA, Altun B, et al. Apolipoprotein E gene polymorphism in renal
641 transplant recipients: effects on lipid metabolism, atherosclerosis and allograft function. *Clin*
642 *Transplant*. 2004;18(3):288-294. doi:10.1111/j.1399-0012.2004.00162.x

643 51. Hernández D, Salido E, Linares J, et al. Role of apolipoprotein E epsilon 4 allele on chronic
644 allograft nephropathy after renal transplantation. *Transplant Proc*. 2004;36(10):2982-2984.
645 doi:10.1016/j.transproceed.2004.10.038

646 52. Cofán F, Cofan M, Rosich E, et al. Effect of apolipoprotein E polymorphism on renal
647 transplantation. *Transplant Proc*. 2007;39(7):2217-2218.
648 doi:10.1016/j.transproceed.2007.06.011

649 53. Czaplińska M, Ćwiklińska A, Sakowicz-Burkiewicz M, et al. Apolipoprotein e gene
650 polymorphism and renal function are associated with apolipoprotein e concentration in
651 patients with chronic kidney disease. *Lipids Health Dis*. 2019;18(1):1-9.
652 doi:10.1186/s12944-019-1003-x

653 54. Hsu CC, Kao WHL, Coresh J, et al. Apolipoprotein E and progression of chronic kidney
654 disease. *J Am Med Assoc*. 2005;293(23):2892-2899. doi:10.1001/jama.293.23.2892

655 55. Saito T, Ishigaki Y, Oikawa S, Yamamoto TT. Etiological significance of apolipoprotein E
656 mutations in lipoprotein glomerulopathy. *Trends Cardiovasc Med*. 2002;12(2):67-70.
657 doi:10.1016/S1050-1738(01)00148-7

658 56. Sienski G, Narayan P, Bonner JM, et al. APOE4 disrupts intracellular lipid homeostasis in
659 human iPSC-derived glia. *Sci Transl Med*. 2021;13(583):eaaz4564.
660 doi:10.1126/scitranslmed.aaz4564

661 57. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk,
662 mechanisms, and therapy. *Nat Rev Neurol*. 2013;9(2):106-118.
663 doi:10.1038/nrneurol.2012.263

664 58. Saddiki H, Fayosse A, Cognat E, et al. Age and the association between apolipoprotein E
665 genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study.
666 *PLoS Med*. 2020;17(8):e1003289. doi:10.1371/journal.pmed.1003289

667 59. Mahley RW, Rall SC. Apolipoprotein E: far more than a lipid transport protein. *Annu Rev*
668 *Genomics Hum Genet*. 2000;1:507-537. doi:10.1146/annurev.genom.1.1.507

669 60. Yao X, Gordon EM, Figueroa DM, Barochia AV, Levine SJ. Emerging Roles of
670 Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung
671 Disease. *Am J Respir Cell Mol Biol*. 2016;55(2):159-169. doi:10.1165/rcmb.2016-0060TR

672 61. Miwa K, Tanaka M, Okazaki S, et al. Chronic kidney disease is associated with dementia
673 independent of cerebral small-vessel disease. *Neurology*. 2014;82(12):1051-1057.
674 doi:10.1212/WNL.0000000000000251

675 62. Huang H, van Dullemen LFA, Akhtar MZ, et al. Proteo-metabolomics reveals compensation
676 between ischemic and non-injured contralateral kidneys after reperfusion. *Sci Rep*.
677 2018;8(1):8539. doi:10.1038/s41598-018-26804-8

678 63. Zhao H, Ji Q, Wu Z, et al. Destabilizing heterochromatin by APOE mediates senescence.
679 *Nature Aging*. 2022;2(4):303-316. doi:10.1038/s43587-022-00186-z

680 64. Julian BA, Gaston RS, Brown WM, et al. Effect of Replacing Race with Apolipoprotein L1
681 Genotype in Calculation of Kidney Donor Risk Index. *Am J Transplant*. 2017;17(6):1540.
682 doi:10.1111/AJT.14113

683 65. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of
684 ageing. *Nat Rev Genet*. 2018;19(6):371-384. doi:10.1038/s41576-018-0004-3

685 66. Meier F, Brunner AD, Frank M, et al. diaPASEF: parallel accumulation–serial fragmentation
686 combined with data-independent acquisition. *Nat Methods*. 2020;17(12):1229-1236.
687 doi:10.1038/s41592-020-00998-0

688 67. Perez-Riverol Y, Csordas A, Bai J, et al. The PRIDE database and related tools and
689 resources in 2019: improving support for quantification data. *Nucleic Acids Res*.
690 2019;47(D1):D442-D450. doi:10.1093/nar/gky1106

691

692 **ACKNOWLEDGMENTS**

693 We thank the UK QUOD Consortium and NHS Blood and Transplant UK Registry; in particular
694 Sheba Ziyenge, Lewis Simmonds and Dr Sarah Cross for the clinical samples and metadata
695 analyzed in this study. We thank Dr Sergei Maslau and Mr Tomas Surik for their support on the
696 QUOD sample selection.

697 We thank members of the Discovery Proteomics Facility within the TDI Mass Spectrometry
698 Laboratory for expert help with mass spectrometry analysis.

## FIGURES AND TABLES




**Figure 1: Experimental design to discover donor kidney proteome associations with transplant outcome** One kidney from each donor pair was biopsied at the back table. Donor kidney samples were selected randomly from pairs where both recipients had similar outcomes. The biopsy samples were subjected to proteomic analysis to yield a snapshot of the organ proteome before transplantation. We analyzed donor characteristics and clinical variables, recipient characteristics and protein abundances in a combined model against outcome.

| Donor Type | DBD | | | DCD | | |
|---|---|---|---|---|---|---|
| Outcome Tertile | 1st: Suboptimal *(eGFR≤39)* | 2nd: Intermediate *(40≤eGFR≤59)* | 3rd: Good *(eGFR≥60)* | 1st: Suboptimal *(eGFR≤39)* | 2nd: Intermediate *(40≤eGFR≤59)* | 3rd: Good *(eGFR≥60)* |
| n | 31 | 31 | 38 | 31 | 28 | 26 |
| Donor Age, y | 56.84 ± 12.29 | 51.32 ± 12.24 | 39.05 ± 14.12 | 55.48 ± 9.34 | 53.57 ± 9.75 | 38.31 ± 12.28 |
| Donor Sex | | | | | | |
| Male | 15 (48.4%) | 16 (51.6%) | 19 (50.0%) | 22 (71.0%) | 16 (57.1%) | 16 (61.5%) |
| Female | 16 (51.6%) | 15 (48.4%) | 19 (50.0%) | 9 (29.0%) | 12 (42.9%) | 10 (38.5%) |
| Donor Ethnicity | | | | | | |
| White | 30 (96.8%) | 30 (96.8%) | 36 (94.7%) | 30 (96.8%) | 28 (100.0%) | 25 (96.2%) |
| Other | 1 (3.2%) | 1 (3.2%) | 2 (5.3%) | 1 (3.2%) | 0 (0.0%) | 1 (3.8%) |
| Donor Weight, kg | 82.53 ± 18.20 | 76.61 ± 18.07 | 81.38 ± 17.72 | 80.58 ± 14.95 | 82.43 ± 17.20 | 78.67 ± 13.96 |
| Donor Height, cm | 168.42 ± 9.37 | 169.52 ± 7.67 | 174.82 ± 11.16 | 169.97 ± 7.98 | 171.64 ± 9.73 | 174.65 ± 8.98 |
| Donor S-Cr terminal, µmol/l | 86.54 ± 40.81 | 82.57 ± 49.65 | 90.19 ± 67.36 | 73.37 ± 19.03 | 70.31 ± 39.02 | 59.60 ± 22.39 |
| Donor CIT, h | 15.80 ± 3.88 | 14.20 ± 4.60 | 13.42 ± 4.67 | 13.65 ± 5.20 | 11.72 ± 3.55 | 12.80 ± 4.49 |
| Donor COD | | | | | | |
| Trauma | 1 (3.2%) | 3 (9.7%) | 3 (7.9%) | 4 (12.9%) | 3 (10.7%) | 4 (15.4%) |
| Other | 30 (96.8%) | 28 (90.3%) | 35 (92.1%) | 27 (87.1%) | 25 (89.3%) | 22 (84.6%) |
| Donor UKKDRI | 1.41 ± 0.52 | 1.10 ± 0.36 | 0.85 ± 0.36 | 1.31 ± 0.37 | 1.21 ± 0.40 | 0.73 ± 0.35 |
| Recipient Age, y | 53.03 ± 12.21 | 52.10 ± 14.61 | 39.71 ± 16.03 | 51.90 ± 9.85 | 50.93 ± 11.04 | 44.92 ± 12.87 |
| Recipient Sex | | | | | | |
| Female | 15 (48.4%) | 8 (25.8%) | 12 (31.6%) | 11 (35.5%) | 9 (32.1%) | 5 (19.2%) |
| Male | 16 (51.6%) | 23 (74.2%) | 26 (68.4%) | 20 (64.5%) | 19 (67.9%) | 21 (80.8%) |
| Recipient Ethnicity | | | | | | |
| White | 24 (77.4%) | 21 (67.7%) | 29 (76.3%) | 22 (71.0%) | 23 (82.1%) | 20 (76.9%) |
| Other | 7 (22.6%) | 10 (32.3%) | 9 (23.7%) | 9 (29.0%) | 5 (17.9%) | 6 (23.1%) |
| Recipient Posttransplant Kidney Function (mean eGFR, mL/min per 1.73 $m^2$) | | | | | | |
| 3 months | 29.71 ± 12.06 | 50.32 ± 17.28 | 78.54 ± 25.97 | 31.72 ± 12.24 | 46.50 ± 10.34 | 77.88 ± 18.57 |
| 12 months | 26.58 ± 11.98 | 49.58 ± 6.10 | 85.58 ± 35.84 | 25.10 ± 12.01 | 48.24 ± 6.29 | 80.26 ± 15.91 |

**Table 1: Donor and recipient clinical and demographic variables**
Donor kidney associated metadata. Samples are subdivided by donor type and by final assigned outcome tertile. Numerical variables are given ± standard deviation. Categorial variables are given alongside percentage of total cohort




**Figure 2: Donor and recipient clinical and demographic data association with recipient 12 month eGFR rank**
Single-linkage hierarchical clustering of curated, imputed clinical variables by relative association strength (taking distance as 1-association). The outcome variable (ranked recipient eGFR at 12 months post-transplantation) is highlighted in red.




**Figure 3: Unbiased analysis of pretransplant kidney proteomes and cluster associations**
A: Unbiased analysis of proteomic data by k-means clustering. Sample separation by Principal Component Analysis. Top Left: Samples were assigned to four clusters by k-means. Bottom & Right: There was a difference in the distribution of DBD and DCD donors across clusters, with the DBD donors being more heavily concentrated in Cluster 2 ('+' symbol; orange shading), and DCD in Cluster 4 ('x' symbol; pink shading)
B: There were no associations between proteome clusters and most donor and recipient factors, except for mildly significant differences in donor BMI and creatinine (selected comparisons shown; left-right, top-bottom: donor type, recipient 12-month posttransplant eGFR (outcome), donor eGFR, donor age, donor BMI, donor creatinine at retrieval).




**Figure 4: Age and combined age:protein related associations link to construction of age-modulated immune metabolic biological networks**

A: Prediction Rule Ensemble (PRE) modelling was performed in an iterative manner to select protein and clinical variable associations with ranked eGFR. At each iteration, only proteins not previously featured in a model were considered. The rules found across all iterations were dominated by donor age terms.

B: Cumulative protein features identified at each iteration. Black line: all features identified by feature selection approach. Blue line: features passing the secondary filter for predictive power and accuracy.

C: Shared Reactome pathway membership network analysis of filtered features. Nodes are colored by assigned cluster, and the clusters are annotated according to the top three most enriched pathways within each cluster.







**Figure 5: Modelled associations between proteins and kidney transplant outcome change with donor age**

A: Ages at which the predicted probability of sub-median outcome is most different between the 10th percentile and 90th percentile of protein abundance. *x* axis: age at which difference is greatest (i.e. when protein has greatest effect). *y* axis: greatest difference.

Proteins above *x*=0 are modelled as having a more negative association with outcome when the protein abundance is high, at that donor age. Proteins below *x*=0 are modelled to have a more positive association with outcome when protein abundance is high, at that donor age.

Proteins with absolute net difference > 0.5 are labelled, as well as the selected proteins VTN, PREB, APOE and CST3.

The inset graphs indicate how the prediction of sub-median outcome ("P(S-M outcome)"; *y* axes) changes with donor age (*x* axes) for labelled proteins. Black trace: prediction at median protein abundance. Purple trace: prediction at 90th percentile of protein abundance. Orange trace: prediction at 10th percentile of protein abundance. The corresponding point on the main figure thus indicates the age at which the difference between orange and purple lines is greatest.

B: Summary of feature selection and modelling analysis


A
ROC AUC (Train)
ROC AUC (Test)
Brier Score (Train)
Brier Score (Test)
Ranked Brier Score Difference
Vitronectin
PREB
APOE
CST3
B
Sensitivity
Specificity
AUC: 0.828
AUC: 0.842
AUC: 0.834
AUC: 0.777
Train
Test
C
P(S-M Outcome)
Donor Age
90th Percentile Abundance
Median (50%ile) Abundance
10th Percentile Abundance
D
Younger; Age ≤ 49
Older; Age ≥ 58
Suboptimal Outcome
Good Outcome
Ratio to Good Outcome mean (log2 scale)
Age ≤ 49, GO
Age ≤ 49, SO
Age ≥ 58, GO
Age ≥ 58, SO
E
Pair 1
Pair 2
Pair 3
Recipient eGFR

747

**Figure 6: Orthogonal validation confirms age-modulated immuno-metabolic proteins predict 12-month transplant outcomes**

A: Validation of models in test dataset. Models are plotted in order of decreasing Brier score (mean squared prediction error) *difference* between test and train data along the x axis. The lower two traces indicate the Brier score in train (purple) and test (green) data. The upper two traces indicate the AUC from the corresponding ROC analyses in train (orange) and test (blue) data.

B-E: Validation of four selected proteins. Left-Right: VTN, PREB, APOE, CST3.

B: Final ROC curves and AUC values for models trained on each protein (and donor age) against test data. The dotted line indicates the original performance against training data.

C: Change in the prediction of sub-median outcome ("P(S-M Outcome)"; *y* axes) with donor age (*x* axes) for each protein. Black trace: prediction at median protein abundance. Purple trace: prediction at $90^{th}$ percentile of protein abundance. Orange trace: prediction at $10^{th}$ percentile of protein abundance. (These are the same as the inset graphs in Figure 5). The light grey and dark grey lines, respectively, indicate the corresponding sampled ages for the western blots below.

D: Western blots comparing younger (age $\leq$ 49) and older (age $\geq$ 58) donors between Good Outcome (GO; eGFR $\geq$ 60) and Suboptimal Outcome (SO; eGFR $\leq$ 40) outcome tertiles. Top row: representative western blots (n=5 per group) from comparison of younger donors. Middle row: representative western blots (n=5 per group) from comparison of older donors. Bottom row: result values for all quantified samples relative to the GO mean. Error bars indicate ±1 standard deviation; the central wider bar indicates mean. Significance stars indicate t-test comparison p-values (***: < 0.001, *: < 0.05).

E: Predicted outcome for six paired Left (L) and Right (R) kidneys from three donors. *x* axes: recipient eGFR at 12 months (i.e. actual outcome). *y* axes: predicted probability of sub-median outcome ("P(S-M Outcome)") using models trained on each protein with donor age. Vertical dotted line indicated median outcome (eGFR = 50). Horizontal dotted line indicates P(Sub-Median Outcome) = 0.5